![April Manness](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profiel
April Manness formerly worked at Luminor Medical Technologies, Inc., as Chief Financial Officer, Luminor Medical Technologies, Inc., as Chief Financial Officer in 2011, Kane Biotech, Inc., as Interim Chief Financial Officer from 2011 to 2012, and DiaMedica Therapeutics, Inc., as Chief Financial Officer.
Eerdere bekende functies van April Manness
| Bedrijven | Functie | Einde |
|---|---|---|
| KANE BIOTECH INC. | Financieel Directeur/CFO | 01-01-2012 |
Luminor Medical Technologies, Inc.
 Luminor Medical Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Provides biotechnology research and development services | Financieel Directeur/CFO | 23-12-2011 |
| DIAMEDICA THERAPEUTICS INC. | Financieel Directeur/CFO | - |
Luminor Medical Technologies, Inc.
Luminor Medical Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Provides biotechnology research and development services | Financieel Directeur/CFO | 17-10-2007 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
4
Eerstegraads connecties
3
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 3 |
|---|---|
Luminor Medical Technologies, Inc.
Luminor Medical Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Provides biotechnology research and development services | Commercial Services |
Kane Biotech, Inc.
 Kane Biotech, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company that manufactures animal health oral care products | Commercial Services |
DiaMedica Therapeutics, Inc.
 DiaMedica Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that engages in development and commercialization of therapeutic treatments from novel recombinant proteins | Health Technology |
